研究单位：[1]Shanghai Henlius Biotech[2]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology Wuhan,Hubei,China[3]Union Hospital,Tongji Medical College of Huazhong University of Science & Technology Wuhan,Hubei,China[4]The 2nd Xiangya Hospital of Central South University Changsha,Hunan,China[5]Neimenggu Chifeng Hospital Chifeng,Inner Mongolia,China[6]Fujian Cancer Hospital Fuzhou,Fujian,China
研究目的：
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.
